Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Bridgebio Oncology Therapeutics › Deerfield Management Company, L.P. cut its BBOT stake below 5% (3.9%) Fund moves
Why it stands out The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Sep 30, 2026
Reporting period Not applicable
Filed with the SEC Nov 13, 2026 passive 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0001193805-26-001463
Data quality Verified: identifiers matched exactly The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Aug 11, 2026 Company filing · Form 8-K · Results Reported its results What came next Oct 30, 2026 Company filing · Form 8-K · Executive change Changed a top executive or board member “On October 30, 2026, Yong Ben, M.D., M.B.A. provided notice of his resignation as the Chief Medical and Development Officer of BridgeBio Oncology Therapeutics, Inc. (the “Company”), effective January 8, 2027.” Nov 10, 2026 Company filing · Form 8-K · Results Reported its results Nov 13, 2026 5% stake Deerfield Management Company, L.P. reported a passive stake (13G) of 3.9% Nov 13, 2026 Insider Officer sold ~$185 of BBOT shares in the open market